Consequences of the 340B Drug Pricing Program
- PMID: 29791824
- PMCID: PMC8320346
- DOI: 10.1056/NEJMc1802999
Consequences of the 340B Drug Pricing Program
Conflict of interest statement
Since publication of their article, the authors report no further potential conflict of interest.
Comment on
-
Consequences of the 340B Drug Pricing Program.N Engl J Med. 2018 May 24;378(21):2053. doi: 10.1056/NEJMc1802999. N Engl J Med. 2018. PMID: 29792408 No abstract available.
-
Consequences of the 340B Drug Pricing Program.N Engl J Med. 2018 May 24;378(21):2053. doi: 10.1056/NEJMc1802999. N Engl J Med. 2018. PMID: 29792409 No abstract available.
References
-
- Young K, Garfield R, Musumeci M, Clemans-Cope L, Lawton E. Medicaid’s Role for Dual-Eligible Beneficiaries; 2013. http://kff.org/medicaid/issue-brief/medicaids-role-for-dual-eligible-ben....
-
- Frakt A. Point and counterpoint on the recent NEJM 340B study. The Incidental Economist. https://theincidentaleconomist.com/wordpress/point-and-counterpoint-on-t.... Published 2018. Accessed February 22, 2018.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources